Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C
Open accessThe DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
NAFLD (non-alcoholic fatty liver disease) is one of the most frequent chronic liver diseases worldwide. The metabolic factors associated with NAFLD are also determinants of liver disease progression in chronic HCV (hepatitis C virus) infection. It has been reported that, besides inducing hepatic fatty acid biosynthesis, LXR (liver X receptor) regulates a set of inflammatory genes. We aimed to evaluate the hepatic expression of LXRα and its lipogenic and inflammatory targets in 43 patients with NAFLD, 44 with chronic HCV infection and in 22 with histologically normal liver. Real-time PCR and Western blot analysis were used to determine hepatic expression levels of LXRα and related lipogenic and inflammatory mediators in the study population. We found that the LXRα gene and its lipogenic targets PPAR-γ (peroxisome-proliferator-activated receptor-γ), SREBP (sterol-regulatory-element-binding protein)-1c, SREBP-2 and FAS (fatty acid synthase) were overexpressed in the liver of NAFLD and HCV patients who had steatosis. Moreover, up-regulation of inflammatory genes, such as TNF (tumour necrosis factor)-α, IL (interleukin)-6, OPN (osteopontin), iNOS (inducible NO synthase), COX (cyclo-oxygenase)-2 and SOCS (suppressors of cytokine signalling)-3, was observed in NAFLD and HCV patients. Interestingly, TNF-α, IL-6 and osteopontin gene expression was lower in patients with steatohepatitis than in those with steatosis. In conclusion, hepatic expression of LXRα and its related lipogenic and inflammatory genes is abnormally increased in NAFLD and HCV patients with steatosis, suggesting a potential role of LXRα in the pathogenesis of hepatic steatosis in these chronic liver diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The increase in DNL, often observed in metabolic diseases, is also due to the overactivation of the transcription factors that stimulate DNL, e.g. sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate-responsive-element-binding-protein (ChREBP), which can promote the development of MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [28]
In the citing paper
“In fact, LXR is a cholesterol sensor, with a central role in the inflammatory control and in the regulation of lipid and glucose metabolism, overexpressed in case of hepatic steatosis [125].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [125]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Classification of chronic viral hepatitis: a need for reassessment
Scheuer, P. J. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90084-o · Cited by 1,576
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
LXR, a nuclear receptor that defines a distinct retinoid response pathway.
Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995) · Genes & Development · doi:10.1101/gad.9.9.1033 · Cited by 1,123
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Cited by
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771
“Hepatic expression of SREBP-1c, ChREBP and other genes involved in lipogenesis are increased in people with hepatic steatosis compared with those who have normal IHTG content (40-44).”
BackgroundPorras, D., Nistal, E., Martínez-Flórez, S., Pisonero-Vaquero, S., Olcoz, J. L., Jover, R., González-Gallego, J., García-Mediavilla, M. V., & Sánchez-Campos, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.037 · Cited by 524
“development by enhancing lipogenesis in in vivo and in vitro models and in the liver of patients [5, 34].”
BackgroundSelf-citationPast, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis
Musso, G., Gambino, R., & Cassader, M. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.11.002 · Cited by 409
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
Duan, Y., Pan, X., Luo, J., Xiao, X., Li, J., Bestman, P. L., & Luo, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880298 · Cited by 358
“The pro-inflammatory effect of IL-6 may be through the suppressor of cytokine signalling-3 (SOCS-3) - sterol regulatory element binding protein-1c (SREBP-1c)- fatty acyl-CoA (FA-CoA) pathway that inhibited insulin signalling and acted to regulate the acute stage response and chronic inflammation (84, 85).”
BackgroundFrancque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state
Hodson, L., & Gunn, P. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0256-9 · Cited by 309
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Negi, C. K., Babica, P., Bajard, L., Bienertova-Vasku, J., & Tarantino, G. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 190
Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic
Hassan, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12082 · Cited by 186
Pu-erh tea ameliorates obesity and modulates gut microbiota in high fat diet fed mice
Ye, J., Zhao, Y., Chen, X., Zhou, H., Yang, Y., Zhang, X., Huang, Y., Zhang, N., Lui, E. M. K., & Xiao, M. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110360 · Cited by 178
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Mechanisms of intrahepatic triglyceride accumulation
Ress, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i4.1664 · Cited by 132
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis
Bellanti, F., Villani, R., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.023 · Cited by 148
Pisonero‐Vaquero, S., Martínez‐Ferreras, Á., García‐Mediavilla, M. V., Martínez‐Flórez, S., Fernández, A., Benet, M., Olcoz, J. L., Jover, R., González‐Gallego, J., & Sánchez‐Campos, S. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400913 · Cited by 129
Self-citationA Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis
Griffett, K., Solt, L. A., El-Gendy, B. E.-D. M., Kamenecka, T. M., & Burris, T. P. (2013) · ACS Chemical Biology · doi:10.1021/cb300541g · Cited by 125
“We hypothesized that either blocking activation of lipogenic enzyme expression or active suppression of these genes in the liver would be one method to treat NAFLD.”
BackgroundInfluentialMiR-155 Has a Protective Role in the Development of Non-Alcoholic Hepatosteatosis in Mice
Miller, A. M., Gilchrist, D. S., Nijjar, J., Araldi, E., Ramirez, C. M., Lavery, C. A., Fernández-Hernando, C., McInnes, I. B., & Kurowska-Stolarska, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072324 · Cited by 117
Wahlang, B., Song, M., Beier, J. I., Falkner, K. C., Al‐Eryani, L., Clair, H. B., Prough, R. A., Osborne, T. S., Malarkey, D. E., States, J. C., et al. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.06.019 · Cited by 127
“Gene expression levels were calculated according to the 2−ΔΔCt method (Livak and Schmittgen, 2001).”
MethodNuclear Receptors as New Perspective for the Management of Liver Diseases
Trauner, M., & Halilbasic, E. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.044 · Cited by 118
Guzmán, C., Benet, M., Pisonero‐Vaquero, S., Moya, M., García‐Mediavilla, M. V., Martínez‐Chantar, M. L., González‐Gallego, J., Castell, J. V., Sánchez‐Campos, S., & Jover, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.12.014 · Cited by 111
Self-citationYang, W., Wang, J., Chen, Z., Chen, J., Meng, Y., Chen, L., Chang, Y., Geng, B., Sun, L., Dou, L., et al. (2017) · Diabetes · doi:10.2337/db16-1172 · Cited by 101
Potent effects of dioscin against obesity in mice
Liu, M., Xu, L., Yin, L., Qi, Y., Xu, Y., Han, X., Zhao, Y., Sun, H., Yao, J., Lin, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep07973 · Cited by 101
Creatine and the Liver: Metabolism and Possible Interactions
Barcelos, R. P., Stefanello, S. T., Mauriz, J. L., Gonzalez-Gallego, J., & Soares, F. A. A. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150722102613 · Cited by 97
Self-citationInteractions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver
Musso, G., Paschetta, E., Gambino, R., Cassader, M., & Molinaro, F. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.006 · Cited by 102
Osteopontin: Versatile modulator of liver diseases
Nagoshi, S. (2014) · Hepatology Research · doi:10.1111/hepr.12166 · Cited by 87
Lancha, A., Rodríguez, A., Catalán, V., Becerril, S., Sáinz, N., Ramírez, B., Burrell, M. A., Salvador, J., Frühbeck, G., & Gómez-Ambrosi, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098398 · Cited by 84
Yilmaz, Y. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05196.x · Cited by 82
Moroorange juice prevents fatty liver in mice
Salomone, F., Volti, G. L., Titta, L., Puzzo, L., Barbagallo, I., Delia, F. L., Zelber-Sagi, S., Malaguarnera, M., Pelicci, P. G., Giorgio, M., et al. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i29.3862 · Cited by 83
The roles of liver X receptor α in inflammation and inflammation‐associated diseases
Zhao, L., Lei, W., Deng, C., Wu, Z. B., Sun, M., Jin, Z., Song, Y., Yang, Z. P., Jiang, S., Shen, M., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30204 · Cited by 84
“…patients, LXRα and its adipogenesis targets, namely, PPARγ and SREBP‐1c, are overexpressed in the liver, and abnormal upregulation of inflammatory genes, such as TNF‐α and IL‐6, is observed, suggesting a potential role of LXRα in the pathogenesis of viral hepatitis (Lima‐Cabello et al., 2011).”
BackgroundHaga, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i46.12989 · Cited by 70
Lee, S. M., Pusec, C. M., Norris, G. H., Jesus, A. D., Díaz‐Ruiz, A., Muratalla, J. T., Sarmento‐Cabral, A., Guzman, G., Layden, B. T., & Córdoba‐Chacón, J. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.003 · Cited by 77
Wang, C., Yuan, R.-S., Zhuang, W., Sun, J., Wu, J., Li, H., & Chen, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0358-5 · Cited by 71
Impaired LXRα Phosphorylation Attenuates Progression of Fatty Liver Disease
Becares, N., Gage, M. C., Voisin, M., Shrestha, E., Martin-Gutierrez, L., Liang, N., Louie, R., Pourcet, B., Pello, O. M., Luong, T. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.094 · Cited by 68
Tuñón, M. J., San‐Miguel, B., Crespo, I., Laliena, A., Vallejo, D., Alvarez, M., Prìeto, J., & González‐Gallego, J. (2013) · Journal of Pineal Research · doi:10.1111/jpi.12063 · Cited by 68
Self-citationVirus-induced changes in mitochondrial bioenergetics as potential targets for therapy
El‐Bacha, T., & Poian, A. T. D. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.09.021 · Cited by 73
PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs
Peyrou, M., Ramadori, P., Bourgoin, L., & Foti, M. (2012) · PPAR Research · doi:10.1155/2012/757803 · Cited by 69
“PPARγ is generally increased in steatotic livers of both animal models of obesity and human obese patients [24, 25].”
BackgroundAuguet, T., Berlanga, A., Guiu‐Jurado, E., Martínez, S., Porras, J. A., Aragonès, G., Sabench, F., Hernández, M., Aguilar, C., Sirvent, J. J., et al. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151222173 · Cited by 77
“[14] included patients with NAFLD and with steatosis related to chronic hepatitis C virus infection in mildly overweight men and women.”
BackgroundResultTargeting liver X receptors in inflammation
Steffensen, K. R., Jakobsson, T., & Gustafsson, J.-Å. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.806490 · Cited by 63
“Furthermore, expression of LXRa was increased in HVC infected patients [109].”
BackgroundRodriguez‐Miguelez, P., Lima‐Cabello, E., Martínez‐Flórez, S., Almar, M., Cuevas, M. J., & González‐Gallego, J. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00780.2014 · Cited by 62
Self-citationFuchs, C. D., Radun, R., Dixon, E. D., Mlitz, V., Timelthaler, G., Halilbasic, E., Herac, M., Jonker, J. W., Ronda, O. A. H. O., Tardelli, M., et al. (2021) · Hepatology · doi:10.1002/hep.32112 · Cited by 64
Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy
Pisonero‐Vaquero, S., González‐Gallego, J., Sánchez‐Campos, S., & García‐Mediavilla, M. V. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150805094940 · Cited by 57
“A complex network of nuclear receptors regulates enzymes, such as fatty acid synthase (FAS), involved in different steps of hepatic de novo lipogenesis [9].”
Self-citationSun, J., Liu, X., Cong, L., Li, H., Zhang, C., Chen, J., & Wang, C. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0533-3 · Cited by 59
Ni, M., Zhang, B., Zhao, J., Feng, Q., Peng, J., Hu, Y., & Zhao, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108778 · Cited by 60
Bonfleur, M. L., Borck, P. C., Ribeiro, R. A., Caetano, L. C., Soares, G. M., Carneiro, E. M., & Balbo, S. L. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.05.019 · Cited by 61
Crespo, I., San‐Miguel, B., Fernández, A. M. C., de Urbina, J. J. O., González‐Gallego, J., & Tuñón, M. J. (2014) · Translational research · doi:10.1016/j.trsl.2014.10.003 · Cited by 55
Self-citationGarcía‐Mediavilla, M. V., Pisonero‐Vaquero, S., Lima‐Cabello, E., Benedicto, I., Majano, P. L., Jorquera, F., González‐Gallego, J., & Sánchez‐Campos, S. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.88 · Cited by 53
Self-citationShao, M., Ye, Z., Qin, Y., & Wu, T. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9154 · Cited by 60
LXR Agonist Regulates the Carcinogenesis of PCa via the SOCS3 Pathway
Fu, W., Yao, J., Huang, Y. H., Li, Q., Li, W., Chen, Z., He, F., Zhou, Z., & Yan, J. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356662 · Cited by 54
Liver X receptors bridge hepatic lipid metabolism and inflammation
Liu, Y., Qiu, D., & Ma, X. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00554.x · Cited by 53
Xing, Y., Zhao, T., Gao, X., & Wu, Y. (2016) · Scientific Reports · doi:10.1038/srep21309 · Cited by 45
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 56
Zhao, Q., Fan, Y., Zhao, J., Gao, S., Zhao, Z., & Wang, K. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12048 · Cited by 48
Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease
Lee, S. M., Muratalla, J. T., Sierra‐Cruz, M., & Córdoba‐Chacón, J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0155 · Cited by 48
Liu, F., Shi, K., Dong, J., Jin, Z., Wu, Y., Cai, Y., Lin, T., Cai, Q., Liu, L., & Zhang, Y. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01256-9 · Cited by 41
Lee, S. M., Muratalla, J. T., Díaz‐Ruiz, A., Remón-Ruiz, P., McCann, M. A., Liew, C. W., Kineman, R. D., & Córdoba‐Chacón, J. (2021) · Endocrinology · doi:10.1210/endocr/bqab175 · Cited by 42
Lee, S. M., Muratalla, J. T., Karimi, S. S., Díaz‐Ruiz, A., Frutos, M. D., Guzman, G., Ramos‐Molina, B., & Córdoba‐Chacón, J. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04629-z · Cited by 41
Hepatitis regulation by the inflammasome signaling pathway
Negash, A. A., & Gale, M. (2015) · Immunological Reviews · doi:10.1111/imr.12279 · Cited by 41
Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers
Feng, Q., Baker, S. S., Liu, W., Arbizu, R. A., Aljomah, G., Khatib, M., Nugent, C. A., Baker, R. D., Forte, T. M., Hu, Y., et al. (2015) · Pathology · doi:10.1097/pat.0000000000000251 · Cited by 35
Zhang, H., Léveillé, M., Courty, É., Güneş, A., Nguyen, B., & Estall, J. L. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00321.2020 · Cited by 36
Molecular mechanisms of fatty liver in obesity
Gan, L., Xiang, W., Xie, B., & Yu, L. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0410-2 · Cited by 44
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
Siculella, L., Tocci, R., Rochira, A., Testini, M., Gnoni, A., & Damiano, F. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.003 · Cited by 34
de Conti, A., Tryndyak, V., Willett, R. A., Borowa‐Mazgaj, B., Watson, A., Patton, R. E., Khare, S., Muskhelishvili, L., Olson, G. R., Avigan, M., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000194r · Cited by 36
Gómez‐Santos, B., de Urturi, D. S., Núñez-García, M., González‐Romero, F., Buqué, X., Aurrekoetxea, I., de Juan, V. G., Gonzalez-Rellan, M. J., García‐Monzón, C., González‐Rodríguez, Á., et al. (2020) · Aging Cell · doi:10.1111/acel.13183 · Cited by 34
“Given that OPN is increased in liver (Lima-Cabello et al., 2010) and serum of NAFLD patients (Nunez‐Garcia et al., 2017), OPN levels were also measured in a cohort of NAFLD patients ( n = 89) (Figure 1b) (Table 1).”
Self-citationAssociation between inflammatory markers and non-alcoholic fatty liver disease in obese children
Duan, Y., Luo, J., Pan, X., Wei, J., Xiao, X., Li, J., & Luo, M. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.991393 · Cited by 37
Zheng, J., Li, Z., Manabe, Y., Kim, M., Goto, T., Kawada, T., & Sugawara, T. (2018) · Lipids · doi:10.1002/lipd.12002 · Cited by 36
Auguet, T., Berlanga, A., Guiu‐Jurado, E., Terra, X., Martínez, S., Aguilar, C., Filiu, E., Alibalic, A., Sabench, F., Hernández, M., et al. (2014) · BioMed Research International · doi:10.1155/2014/502542 · Cited by 32
Gao, W.-Y., Chen, P., Hsu, H., Lin, C.-Y., Wu, M., & Yen, J.-H. (2021) · Biomedicines · doi:10.3390/biomedicines9030326 · Cited by 36
Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease
Serviddio, G., Blonda, M., Bellanti, F., Villani, R., Iuliano, L., & Vendemiale, G. (2013) · Free Radical Research · doi:10.3109/10715762.2013.835048 · Cited by 30
Vallejo, D., Crespo, I., San‐Miguel, B., Alvarez, M., Prìeto, J., Tuñón, M. J., & González‐Gallego, J. (2014) · Veterinary Research · doi:10.1186/1297-9716-45-15 · Cited by 36
“Relative changes in gene expression levels were determined using the 2-DDCt method [27] .”
MethodSelf-citationHepatitis C Virus, Oxidative Stress and Steatosis: Current Status and Perspectives
González‐Gallego, J., García‐Mediavilla, M. V., & Sánchez‐Campos, S. (2011) · Current Molecular Medicine · doi:10.2174/156652411795976592 · Cited by 30
Self-citationBitter, A., Nussler, A. K., Thasler, W. E., Klein, K., Zanger, U. M., Schwab, M. G., & Burk, O. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000369739 · Cited by 31
Nawaz, R., Zahid, S., Idrees, M., Rafique, S., Shahid, M., Ahad, A., Amin, I., Almas, I., & Afzal, S. (2017) · Inflammation Research · doi:10.1007/s00011-017-1029-3 · Cited by 33
Yilmaz, Y. N., Öztürk, O., Alahdab, Y. Ö., Şenateş, E., Çolak, Y., Doğanay, H. L., Coşkunpınar, E. M., Oltulu, Y. M., Eren, F., Atuğ, Ö., et al. (2012) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.08.017 · Cited by 28
Ramalingam, P. S., Elangovan, S., Ramaiah, M. J., & Arumugam, S. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1386102 · Cited by 27
Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways
Young, K.-C., Bai, C., Su, H., Tsai, P., Pu, C.-Y., Liao, C., Lin, Y., Lai, H.-W., Chong, L.-W., Tsai, Y.-S., et al. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.08.002 · Cited by 26
Fatty acid binding profile of the liver X receptor α
Bedi, S., Hines, G. V., Lozada-Fernandez, V. V., Piva, C. D. J., Kaliappan, A., Rider, S. D., & Hostetler, H. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m072447 · Cited by 26
Na, T., Han, Y., Ka, N., Park, H., Kang, Y. P., Kwon, S. W., Lee, B., & Lee, M. (2014) · The Journal of Pathology · doi:10.1002/path.4494 · Cited by 25
Pascarella, S., Clément, S., Guilloux, K., Conzelmann, S., Penin, F., & Negro, F. (2011) · Journal of Medical Virology · doi:10.1002/jmv.22072 · Cited by 25
Ethanol and fatty acids impair lipid homeostasis in an in vitro model of hepatic steatosis
Vecchione, G., Grasselli, E., Compalati, A. D., Ragazzoni, M., Cortese, K., Gallo, G., Voci, A., & Vergani, L. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.02.004 · Cited by 22
Sofer, E., & Shargorodsky, M. (2015) · Hepatology International · doi:10.1007/s12072-015-9649-6 · Cited by 21
Ethanol extract of Allium fistulosum inhibits development of non-alcoholic fatty liver disease
Hwang, J., Shin, E. J., Chung, M., Park, J. H., Chung, S., & Choi, H. (2018) · Nutrition Research and Practice · doi:10.4162/nrp.2018.12.2.110 · Cited by 20
“Lipogenic targets such as PPAR-γ, SREBP-1c, and FASN were overexpressed in the liver of the patients with abnormally increased inflammation from hepatitis C virus infection with hepatic steatosis [35].”
BackgroundLi, Z., Zheng, D., Zhang, T., Ruan, S., Li, N., Yang, Y., Yang, P., & Wang, D. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000343 · Cited by 29
Zhang, Y., Fan, X., Qiu, L., Zhu, W., Huang, L., & Miao, Y. (2021) · Journal of Dairy Science · doi:10.3168/jds.2021-20596 · Cited by 19
Watanabe, S., & Tsuneyama, K. (2012) · The Journal of Toxicological Sciences · doi:10.2131/jts.37.105 · Cited by 25
Dong, D., Qi, Y., Xu, L., Yin, L., Xu, Y., Han, X., Zhao, Y., & Peng, J. (2014) · Food & Function · doi:10.1039/c4fo00491d · Cited by 20
Errafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17
Zaiou, M. (2023) · Cells · doi:10.3390/cells12081205 · Cited by 20
Li, X., & Li, M. (2024) · Pharmaceuticals · doi:10.3390/ph17081073 · Cited by 20
“…(HCV)-afflicted patients with steatosis, hep-atic LXR α expression, alongside lipogenic (e.g., PPAR-γ , SREBP-1c, SREBP-2, and FAS) and inflammatory genes (e.g., TNF-α , IL-6, and iNOS), is abnormally increased, pointing to the conceivable role of LXR α in these liver conditions’ pathogenesis [84].”
BackgroundHigh-fat diet alters PAS kinase regulation by fasting and feeding in liver
Pérez-García, A., Dongil, P., Hurtado-Carneiro, V., Blázquez, E., Sanz, C., & Álvarez, E. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.03.003 · Cited by 18
Theoretical basis of a beneficial role for vitamin D in viral hepatitis
Lương, K. V. Q. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i38.5338 · Cited by 18
Hyperinsulinaemia: does it tip the balance toward intrahepatic fat accumulation?
Hodson, L., & Karpe, F. (2019) · Endocrine Connections · doi:10.1530/ec-19-0350 · Cited by 18
Liver steatosis in hepatitis C patients
González‐Reimers, E., Quintero-Platt, G., Rodríguez-Gaspar, M., Alemán-Valls, R., Pérez-Hernández, O., & Santolaria-Fernández, F. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i10.1337 · Cited by 17
Prostaglandin I 2 suppresses the development of diet‐induced nonalcoholic steatohepatitis in mice
Kumei, S., Yuhki, K., Kojima, F., Kashiwagi, H., Imamichi, Y., Okumura, T., Narumiya, S., & Ushikubi, F. (2017) · The FASEB Journal · doi:10.1096/fj.201700590r · Cited by 17
Emerging Insights into Liver X Receptor α in the Tumorigenesis and Therapeutics of Human Cancers
Han, N., Yuan, M., Yan, L., & Tang, H. (2023) · Biomolecules · doi:10.3390/biom13081184 · Cited by 17
Senoinflammation as the underlying mechanism of aging and its modulation by calorie restriction
Noh, S. G., Kim, H., Kim, S., Chung, K. W., Jung, Y.-S., Yoon, J.-H., Yu, B. P., Lee, J., & Chung, H. Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102503 · Cited by 16
Lin, Y.-M., Sun, H.-Y., Chiu, W., Su, H. C., Chien, Y.-C., Chong, L.-W., Chang, H., Bai, C. H., Young, K. C., & Tsao, C.-W. (2018) · Viruses · doi:10.3390/v10020057 · Cited by 16
Activation of Liver X Receptor α Sensitizes Mice to T‐Cell Mediated Hepatitis
Gao, L., Li, B., Wang, J., Shen, D., Yang, M., Sun, R., Tung, H., Xu, M., Ren, S., Zhang, M., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1584 · Cited by 12
“Because LXRα has been reported to display an abnormal expression in several liver diseases, including nonalcoholic fatty liver disease, and hepatitis B and C virus–associated hepatic steatosis,(21,22) we initially wondered whether the expression of LXRs is also affected in the ConA model of hepatitis.”
BackgroundLiu, Z., Nahon, P., Li, Z., Yin, P., Li, Y., Amathieu, R., Ganne‐Carrié, N., Ziol, M., Sellier, N., Séror, O., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23500 · Cited by 12
Metadata
- Authors
- Lima-Cabello, E., García-Mediavilla, M. V., Miquilena-Colina, M. E., Vargas-Castrillón, J., Lozano-Rodríguez, T., Fernández-Bermejo, M., Olcoz, J. L., González-Gallego, J., García-Monzón, C., & Sánchez-Campos, S.
- Affiliations
- Institute of Biomedicine (IBIOMED), University of León, León, Spain
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
- Gastroenterology Service, San Pedro de Alcántara Hospital, Cáceres, Spain
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2010-12-03
- Volume
- 120
- Issue
- 6
- Pages
- 239-250
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2005558543
- Cited by
- 144
- References
- 45
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 8 · 2018: 5 · 2017: 11 · 2016: 11 · 2015: 17 · 2014: 17 · 2013: 11 · 2012: 12
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-06-19)
- Open access
- bronze
- doi.org
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Funders
- Fundación Eugenio Rodríguez Pascual
- Junta de Castilla y León
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- non-alcoholic fatty liver disease, hepatitis C, liver X receptor alpha, hepatic steatosis, steatohepatitis, pro-inflammatory gene expression, lipogenic genes, PPARγ, SREBP-1c, SREBP2, fatty acid synthase, TNF-α, interleukin-6, osteopontin, inducible nitric oxide synthase, cyclooxygenase-2, liver inflammation
- MeSH terms
- Liver X Receptors, Adult, Fatty Liver, Female, Gene Expression Regulation, Humans, Liver, Male, Middle Aged, Up-Regulation, Oxidative Stress, Inflammation Mediators, Hepatitis C, Chronic, Lipogenesis, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.